Pharmac update: Concerta supply issues

From 1 March 2024 the Special Authority criteria for Concerta and Ritalin LA has been amended. This removes the criterion allowing treatment initiation on to Concerta or Ritalin LA if unable to access Teva-ER due to supply issues.

This is because all strengths of Methylphenidate ER - Teva, are available again. However supply of Concerta is now constrained. 

Supply constraints with Concerta

There is pressure on the supply of Concerta, particularly the 27mg strength. This strength is expected to be constrained from April 2024 and over the following months.

Pharmac is working closely with Janssen, the supplier of Concerta, to understand the supply outlook and any improvements in supply that can be made. 

Actions for prescribers

• Methylphenidate ER – Teva can once again be prescribed when starting people on methylphenidate. All strengths of this brand have been back in stock since November 2023.
• People who were originally prescribed the Teva brand and who have moved to Concerta should be transitioned back.
• Please reassure affected people that clinical advice indicates it is safe to transition between the Concerta and Teva-ER brands
• If an individual’s approval for Methylphenidate ER – Teva has lapsed, we encourage you to apply for a renewal if eligible, to enable them to return to the Teva brand.

Pharmac appreciate your support in helping manage this supply issue and ensuring access to Concerta is maintained. If you have questions, please email enquiry@pharmac.govt.nz. See the Pharmac website for more information.